Project Grant R01HL174587

Award Date 7/1/24
Completion Date 4/30/29
Dollars Obligated $2.2M
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Houston, TX 77030, USA
Similar Awards
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $3,717,718 Cooperative Agreement under the Cardiovascular Diseases Research program (CFDA 93.837) to Duke University to conduct the "LOW DOSE COLCHICINE IN PATIENTS WITH PERIPHERAL ARTERY DISEASE TO ASSESS RESIDUAL VASCULAR RISK (LEADER-PAD)" clinical trial. This 4-year study, starting on September 25, 2024, aims to enroll 1,000 U.S. participants as part of a larger 6,150-patient international trial. The trial will...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) totaling $687,517 will support research at the University of Alabama at Birmingham (UAB) to elucidate the relationship between the gene Leiomodin1 (LMOD1) and peripheral artery disease (PAD). The key objectives are to: Use cell culture models and translational approaches to determine the mechanistic pathway by which reduced LMOD1 mediates impaired neovessel...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $2,529,292 Cooperative Agreement under CFDA 93.837 (Cardiovascular Diseases Research) to Northwestern University on September 17, 2024. The project, titled "Improving Mobility After Revascularization in Peripheral Artery Disease: The IMPACT PAD Trial," aims to assess the impact of home-based exercise and nitrate-rich beetroot juice on walking performance in patients who have undergone lower extremity revascularization...
This Project Grant award for $691,708.00 from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research (CFDA 93.837) program supports the development of a novel contrast-free ultrasound-based quantitative angio flow imaging technique to assess peripheral arterial disease (PAD) of the lower limbs. The research project aims to determine the efficacy of this new "Angio Flow Reactivity Analysis" (AFRA) method for assessing PAD in patient...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $395,306 to Cutcath LLC to develop and evaluate a novel electrosurgical catheter device for treating acute aortic dissection. The device, called the Cutcath Dissection Septum Cutting Catheter (DSCC), aims to facilitate more effective endovascular aortic repair (TEVAR/EVAR) by allowing complete fenestration of the aortic dissection septum....
This federal Project Grant award of $761,042 from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) aims to investigate the mechanisms driving medial arterial calcification (MAC) in peripheral artery disease (PAD). The research, conducted by the University of Pittsburgh, will test the hypothesis that reduced CD73-mediated adenosine production alters arginine methylation to promote osteogenic gene transcription in smooth muscle cells, leading to MAC...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under CFDA 93.837 - Cardiovascular Diseases Research provides $1,306,060 to the University of Louisville to conduct a clinical trial investigating the use of carnosine supplementation as a therapeutic intervention for patients with peripheral arterial disease (PAD). The goal is to determine if carnosine, which can help buffer pH and improve metabolic function in ischemic skeletal muscle, can improve lower...
This Project Grant award of $786,188, provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), aims to develop a novel gene therapy platform to prevent the failure of prosthetic bypass grafts used to treat arterial blockages in the lower extremities. The research, conducted by Beth Israel Deaconess Medical Center, Inc. (BIDMC), focuses on optimizing a biodegradable hydrogel system that can deliver small interfering RNA...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $2,158,878 to the Rector & Visitors of the University of Virginia (UVA) to advance research on mitigating intimal hyperplasia (IH), a condition that can re-narrow arteries after angioplasty procedures. The key objectives are to: 1) Resolve the endothelial cell-specific role of the enzyme ALDH1A3 in IH pathophysiology and its...
The National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research (CFDA 93.837) program, awarded a $413,595 Project Grant to Unandup, LLC, a medical technology firm based in St. Louis, Missouri. The grant will fund the development of a magnetic rotational atherectomy platform to debulk severely calcified coronary lesions and improve percutaneous coronary intervention procedures. Key innovations include the use of magnetic fields to control the atherectomy...

ADVANCING ENDOVASCULAR PAD TREATMENT: OVERCOMING CRITICAL KNOWLEDGE GAPS WITH MRI-HISTOLOGY - ABSTRACT PERIPHERAL ARTERY DISEASE (PAD) CAUSES SEVERE MORBIDITY AS PLAQUES OBSTRUCT BLOOD FLOW, PREVENTING ADEQUATE PERFUSION TO LIMBS, WHICH MAY RESULT IN AMPUTATION OR DEATH. THERE ARE ONE MILLION INTERVENTIONS TO TREAT PAD PER YEAR, EMPHASIZING THE HIGH PREVALENCE OF THIS DISEASE. THE PREFERRED TREATMENT IS PERCUTANEOUS VASCULAR INTERVENTIONS (PVI), WHERE VESSEL PLAQUE IS PENETRATED AND THREADED (CROSSED) BY A GUIDEWIRE, FOLLOWED BY A BALLOON OVER THE WIRE AND/OR OTHER ADJUNCTIVE DEVICES TO OPEN THE BLOOD VESSEL. UNFORTUNATELY, PVI FAILS IMMEDIATELY FOR 20% OF PATIENTS BECAUSE THE PLAQUE PROVES IMPENETRABLE -- MEANING PATIENTS ARE PUT AT RISK FOR NO HEALTH BENEFIT. FURTHERMORE, AFTER BALLOONING OPEN THERE IS DAMAGE TO THE VESSEL WALL AND VESSELS BLOCK AGAIN WITHIN A YEAR FOR 70% OF PATIENTS WITH BELOW-THE-KNEE PLAQUES. THESE FAILURES THEN REQUIRE ADDITIONAL INVASIVE INTERVENTIONS. THE DIFFICULTIES WITH PVI ARE FRUSTRATING FOR THE CLINICIANS PERFORMING THE SURGERY AND NEEDLESSLY RISKY FOR OUR PATIENTS. THERE IS A FUNDAMENTAL GAP IN KNOWLEDGE IN HOW TO SELECT PATIENTS THAT BENEFIT FROM PVI AND HOW DIFFERENT PREPARATION DEVICES ALTER VESSEL WALL INJURY. WE PROPOSE A TWO-PRONGED APPROACH: 1) IMPROVE PATIENT SELECTION FOR PVI USING A NOVEL MRI-HISTOLOGY BASED ANATOMIC SCORING SYSTEM THAT IDENTIFIES PATIENTS WITH IMPENETRABLE PLAQUES; AND 2) IMPROVE DEVICE SELECTION BY IDENTIFYING DEVICES THAT REDUCE VESSEL WALL INJURY DURING PVI USING HISTOPATHOLOGIC ANALYSIS AFTER PVI IN A CADAVERIC MODEL. OUR PRELIMINARY DATA SHOW THAT OUR IN VIVO MRI-HISTOLOGY METHOD CAN VISUALIZE HARD PLAQUE COMPONENTS (BOTH CALCIUM AND DENSE COLLAGEN) TO DECIPHER INDIVIDUAL PATIENTS' PLAQUE MORPHOLOGY AND DETERMINE WHICH PLAQUES ARE PENETRABLE. FURTHERMORE, OUR CADAVERIC MODEL INDICATES DIFFERENCES IN VESSEL WALL INJURY FOLLOWING DIFFERENT PREPARATION DEVICES USING DETAILED EX VIVO PLAQUE ANALYSIS POST-INTERVENTION. OUR SPECIFIC AIMS ARE: 1. ESTABLISH A NOVEL MRI-HISTOLOGY ANATOMIC SCORING SYSTEM THAT PREDICTS PVI IMMEDIATE TECHNICAL FAILURE TO IMPROVE PATIENT SELECTION FOR PVI. WE WILL IMAGE PATIENTS PRIOR TO THEIR PVI WITH OUR CLINICAL MRI-HISTOLOGY PROTOCOL TO PROSPECTIVELY SCORE INDIVIDUAL PATIENTS' PLAQUES TO PREDICT SUCCESSFUL GUIDEWIRE CROSSING. 2. DESCRIBE THE BENEFITS OF USING ORBITAL ATHERECTOMY BEFORE BALLOON ANGIOPLASTY VERSUS USING BALLOON ANGIOPLASTY ALONE FOR VARIOUS PLAQUE TYPES IN ARTERIES BELOW THE KNEE. WE WILL RANDOMIZE AMPUTATED LEGS FROM PAD PATIENTS WITH CALCIFIED BELOW-THE-KNEE ARTERIES TO UNDERGO PLAIN BALLOON ANGIOPLASTY VERSUS ATHERECTOMY PREPARATION DEVICE PRIOR TO ANGIOPLASTY. PRE-PROCEDURE 3T MRI-HISTOLOGY, INTRAVASCULAR ULTRASOUND, AND EX VIVO PLAQUE ANALYSIS WITH HISTOLOGY, WILL DETERMINE VESSEL WALL INJURY BETWEEN INTERVENTION GROUPS. WE WILL ESTABLISH A PATIENT SELECTION PROCESS FOR PVI AND DEFINE VESSEL WALL RESPONSE WITH BALLOONING ONLY VERSUS VESSEL PREPARATION WITH ATHERECTOMY THROUGH HISTOLOGIC ANALYSIS OF CADAVERIC LESIONS. OUR STUDY WILL EMPOWER CLINICAL DECISION-MAKING TOWARD THE SAFEST, MOST EFFECTIVE STRATEGIES TO ULTIMATELY SAVE PATIENT LIMBS AND LIVES.

Posted 6/15/24, 12:00 AM